Gelonghui, April 26 | ResMed (RMD.US), an Australian sleep and respiratory equipment manufacturing company, rose 11.22% before the market opened and was quoted at $204.
According to the news, the company\’s 2024 Q3 financial report achieved revenue of US$1.197 billion. The previous value was US$1.1169 billion. The expected value was US$1.17 billion; earnings per share was US$2.13. The previous value was US$1.68. The expected value was US$1.91.
ResMed rose more than 11% before the market opened, and its 2024 third fiscal quarter results exceeded expectations.
Gelonghui April 26｜ResMed (RMD.US), an Australian sleep and breathing equipment manufacturing company, rose 11.22% before the market opened to US$204.
Like (0)
Chinese concept stocks generally rose before the market opened, with Xpeng Motors rising nearly 8%
Previous
April 26, 2024 4:38 pm